GALT - Galectin Therapeutics Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

GALT

GALECTIN THERAPEUTICS INC.

NASDAQ

$3.64

▲ UP 0.55% (0.02)

KEY STATISTICS

Market Cap$238.70 M

52w High$7.13

52w Low$2.03

Dividend Yield—

Frequency—

P/E-8.88

Volume270.82K

Shares Out.65.86M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Joel Lewis

COMPENSATION 2026

Salary$620,167

Stock Awards$202,635

Incentive Plan Pay$0

All Other Comp.$54,872

Total$1,189,674

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 4, 2002

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

PRICE TARGET

Target High$11.00

Target Low$11.00

Target Median$11.00

Target Consensus$11.00

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2012-03-23	Reverse	1:6

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

18.51%

HOLDERS

154

TOP 8 OF 154 · RANKED BY POSITION SIZE

Geode Capital Management, LLC

1.3M sh

$6.07M

Advisor Group Holdings, Inc.

Millennium Management LLC

798.4K sh

$2.23M

PRICE

$3.64 ▲ UP 0.55% (+$0.02)

OVERLAYS

About Galectin Therapeutics Inc.

https://galectintherapeutics.com ↗

Galectin Therapeutics Inc. is a clinical-stage biopharma developing galectin-3 inhibitors like belapectin for fibrotic, cancer, and other diseases, with lead candidates in Phase III trials for liver fibrosis and NASH cirrhosis.

INDUSTRY

Biotechnology

A PRODUCT GALECTIN THERAPEUTICS INC. IS KNOWN FOR

Belapectin (GR-MD-02)

Belapectin, Galectin Therapeutics' lead drug, is a carbohydrate-based therapy targeting galectin-3, in clinical trials for MASH with cirrhosis and combined with immunotherapy for advanced melanoma and head and neck cancers.

COMPETITORS

COMPETITOR

IVA COMPARE

MDGL COMPARE

Galectin Therapeutics in 2025

SENTIMENT: − NEGATIVE

REGULATORY · DECEMBER 19, 2025

Galectin Therapeutics Receives FDA Feedback on Belapectin, Secures $10 Million Financing, and Stock Plummets

Galectin Therapeutics announced it received a written response from the U.S. Food and Drug Administration (FDA) regarding the development program for its lead drug candidate, belapectin. While the company stated there is alignment with the FDA on the patient population for a future registration trial, the necessity for a follow-up meeting to finalize the trial design, combined with a concurrent announcement of a new $10 million credit line, was met with a significant negative market reaction. The stock price experienced a sharp decline of 28.90% on the day of the announcement, indicating this was the most notable event for the company in 2025.

CAPITAL ALLOCATION · DECEMBER 2025 · COMPLETED

Galectin Therapeutics Secures Critical Insider Financing to Extend Operational Runway and Pursue Pivotal Phase 3 Trial for Belapectin

In a pivotal strategic move, Galectin Therapeutics secured an additional $10 million in convertible debt from its chairman in December 2025, extending its cash runway into 2027. This decision, combined with a similar financing in July, underscores a deliberate strategy to rely on insider funding to navigate a critical period of regulatory discussions with the FDA for its lead drug candidate, belapectin, following mixed feedback on its trial design.

Latest News

GLOBENEWSWIRE · OCT 6, 2026

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.

READ ARTICLE